Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 3Thoracic 1Genitourinary 1Breast 1

Conditions

Prostatic Neoplasms 18Urinary Bladder Neoplasms 3Breast Neoplasms 2Recurrence 1Prostate Cancer Metastatic 1Parkinson Disease 1Neoplasms 1Lung Neoplasms 1Head and Neck Neoplasms 1Glioma 1Disease 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 20atezolizumab 8Nivolumab 8Docetaxel 7Carboplatin 6cemiplimab 5Immune Checkpoint Inhibitors 5Radiotherapy 4Paclitaxel 4Filgrastim 4Drug Therapy 4fludarabine 3durvalumab 3Radiosurgery 3Pemetrexed 3Gemcitabine 3Fluorouracil 3Cyclophosphamide 3Cisplatin 3Cetuximab 3Bortezomib 3niraparib 2motexafin gadolinium 2belinostat 2avelumab 2amminedichloro(2-methylpyridine)platinum(II) 2aldesleukin 2Tobacco Use Cessation Devices 2Tetrahydrouridine 2Taxes 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × Positron Emission Tomography Computed Tomography × Genitourinary × Clear all
NCT01479348 2020-06-02

Imaging Study for FdCyd and THU Cancer Treatment

National Institutes of Health Clinical Center (CC)

Phase EARLY_PHASE1 Terminated
5 enrolled 12 charts
BreastGenitourinaryHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡